February 16, 2022
A German court has set aside a €142 million ($161.8 million) damages award issued to Austrian pharmaceutical company AOP Orphan in the midst of a contentious dispute with Taiwanese drug developer PharmaEssentia Corp. over an ill-fated deal to develop a new blood cancer treatment.
January 20, 2022
AOP Orphan has asked authorities in Germany to investigate allegedly deceptive statements a Taiwanese drug developer made during arbitration over an ill-fated deal to develop a new blood cancer treatment, including a proceeding in which the Austrian pharmaceutical company was awarded €140 million.